A mild Lewis acid mediated epoxy-ester to bicyclic ortho ester rearrangement
作者:Awais Ahmed、Steven D. R. Christie、Mark R. J. Elsegood、Gareth J. Pritchard
DOI:10.1039/c3cc44364g
日期:——
A high yielding rearrangement of epoxy-esters, under Lewisacid conditions, to give bicyclic ortho esters is reported.
据报道,在路易斯酸条件下,环氧酯的高产率重排以得到双环原酸酯。
Total Synthesis of (−)-Mitrephorone A Enabled by Stereoselective Nitrile Oxide Cycloaddition and Tetrasubstituted Olefin Synthesis
作者:Michael Schneider、Matthieu J. R. Richter、Erick M. Carreira
DOI:10.1021/jacs.0c09520
日期:2020.10.14
highly enantioselective and diastereoselective totalsynthesis of the diterpenoid (−)-mitrephorone A is presented. Key to the synthesis are stereocontrolled 1,4-semihydrogenation of a 1,3-diene to a tetrasubstituted double bond, enzyme-catalyzed malonate desymmetrization, and highly diastereoselective nitrile oxide cycloaddition. The streamlined strategy is a considerable improvement to those reported
提出了二萜 (-)-mitrephorone A 的高度对映选择性和非对映选择性全合成。合成的关键是立体控制的 1,3-二烯 1,4-半氢化生成四取代双键、酶催化丙二酸去对称化和高度非对映选择性的氧化腈环加成反应。在非对映选择性和对映选择性方面,简化的策略比之前报道的策略有了相当大的改进。现代 Pd 交叉偶联与 Cr 催化还原的结合首次允许快速获得具有完全立体控制的四取代烯烃。
INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME
申请人:Rohde J. Jeffrey
公开号:US20070179186A1
公开(公告)日:2007-08-02
The present invention relates to compounds that are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme, The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.
Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
申请人:Bitner R. Scott
公开号:US20120289512A1
公开(公告)日:2012-11-15
The present invention relates to inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.